D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Biology and Biochemistry D-index 44 Citations 7,119 104 World Ranking 13570 National Ranking 5765

Overview

What is he best known for?

The fields of study he is best known for:

  • Enzyme
  • Cancer
  • Amino acid

Andrew P. Mazar spends much of his time researching Cancer research, Urokinase receptor, Angiogenesis, Metastasis and Plasminogen activator. His Cancer research research focuses on Apoptosis and how it connects with KRAS, Lung cancer, Endocrinology and Chemotherapy. His work carried out in the field of Urokinase receptor brings together such families of science as Cell adhesion and Cell biology.

Andrew P. Mazar interconnects Cell and Antimetabolite in the investigation of issues within Angiogenesis. His studies in Metastasis integrate themes in fields like Intraperitoneal injection, Colorectal cancer and Combination therapy. His research integrates issues of Prostate, Cell growth, Growth factor, Biological activity and Primary tumor in his study of Plasminogen activator.

His most cited work include:

  • Structure of Human Urokinase Plasminogen Activator in Complex with Its Receptor (240 citations)
  • Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. (212 citations)
  • Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. (199 citations)

What are the main themes of his work throughout his whole career to date?

Andrew P. Mazar mostly deals with Urokinase receptor, Cancer research, Molecular biology, Urokinase and Angiogenesis. While the research belongs to areas of Urokinase receptor, Andrew P. Mazar spends his time largely on the problem of Cell biology, intersecting his research to questions surrounding Integrin and Cell adhesion. His Cancer research study combines topics in areas such as Cancer, Metastasis, Tumor progression, In vitro and Immunology.

He has included themes like Transfection, Antibody, Monoclonal antibody, Vitronectin and Binding site in his Molecular biology study. Andrew P. Mazar combines subjects such as Fibrinolysis and Pathology with his study of Urokinase. His study looks at the intersection of Angiogenesis and topics like Biochemistry with Copper metabolism.

He most often published in these fields:

  • Urokinase receptor (44.30%)
  • Cancer research (29.53%)
  • Molecular biology (32.21%)

What were the highlights of his more recent work (between 2008-2021)?

  • Cancer research (29.53%)
  • Cancer (15.44%)
  • Urokinase receptor (44.30%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Cancer research, Cancer, Urokinase receptor, Kinase and Metastasis. His research in Cancer research intersects with topics in Cell growth, Immunology, Primary tumor, Tumour dormancy and Adenocarcinoma. As part of the same scientific family, Andrew P. Mazar usually focuses on Cancer, concentrating on Apoptosis and intersecting with KRAS and Lung cancer.

His research in Urokinase receptor focuses on subjects like Mesothelial Cell, which are connected to Pathophysiology. His Metastasis research is multidisciplinary, incorporating perspectives in Metastatic breast cancer, Pathology, Cell adhesion, Bone cancer and Extracellular matrix. In his study, Urokinase is inextricably linked to Molecular biology, which falls within the broad field of SOD1.

Between 2008 and 2021, his most popular works were:

  • Targeting SOD1 Reduces Experimental non–small-cell Lung Cancer (118 citations)
  • An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. (66 citations)
  • Targeting the Urokinase Plasminogen Activator Receptor Inhibits Ovarian Cancer Metastasis (57 citations)

In his most recent research, the most cited papers focused on:

  • Enzyme
  • Cancer
  • Amino acid

Cancer research, Metastasis, Cancer, Urokinase receptor and Cell growth are his primary areas of study. His studies deal with areas such as Primary tumor, Organoid and Adenocarcinoma as well as Cancer research. His work deals with themes such as Extracellular matrix, Ovarian cancer, Cell adhesion and Pathology, which intersect with Metastasis.

The concepts of his Cancer study are interwoven with issues in Endocrinology and Angiogenesis. His Urokinase receptor study incorporates themes from Protein kinase B, Protein kinase A, Cancer cell, Liver cancer and Prostate cancer. His study in Cell growth is interdisciplinary in nature, drawing from both SOD1, Molecular biology, KRAS, Lung cancer and Programmed cell death.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Structure of Human Urokinase Plasminogen Activator in Complex with Its Receptor

Qing Huai;Andrew P. Mazar;Alice Kuo;Graham C. Parry.
Science (2006)

308 Citations

Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.

Shafaat A. Rabbani;Andrew P. Mazar;Suzanne M. Bernier;Mahmudul Haq.
Journal of Biological Chemistry (1992)

303 Citations

Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice

Oliver Stoeltzing;Wenbiao Liu;Niels Reinmuth;Fan Fan.
International Journal of Cancer (2003)

278 Citations

Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor.

Robert W. Colman;Robin A. Pixley;Syeda Najamunnisa;Wuyi Yan.
Journal of Clinical Investigation (1997)

265 Citations

AN AMINO-TERMINAL FRAGMENT OF UROKINASE ISOLATED FROM A PROSTATE CANCER CELL LINE (PC-3) IS MITOGENIC FOR OSTEOBLAST-LIKE CELLS

Shafast A. Rabbani;Johanne Desjardins;Alexander W. Bell;Denis Banville.
Biochemical and Biophysical Research Communications (1990)

248 Citations

Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling

Jose C. Juarez;Mari Manuia;Mark E. Burnett;Oscar Betancourt.
Proceedings of the National Academy of Sciences of the United States of America (2008)

245 Citations

Urokinase-type Plasminogen Activator Receptor (CD87) Is a Ligand for Integrins and Mediates Cell-Cell Interaction

Takehiko Tarui;Andrew P. Mazar;Douglas B. Cines;Yoshikazu Takada.
Journal of Biological Chemistry (2001)

236 Citations

The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis.

Andrew P. Mazar;Jack Henkin;Ronald H. Goldfarb.
Angiogenesis (1999)

235 Citations

The role of the plasminogen activation system in angiogenesis and metastasis.

Shafaat A. Rabbani;Andrew P. Mazar.
Surgical Oncology Clinics of North America (2001)

235 Citations

A non–RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo

Parisa Khalili;Ani Arakelian;Gaoping Chen;Marian L. Plunkett.
Molecular Cancer Therapeutics (2006)

194 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Andrew P. Mazar

Douglas B. Cines

Douglas B. Cines

University of Pennsylvania

Publications: 64

Michael Ploug

Michael Ploug

University of Copenhagen

Publications: 49

Robert W. Colman

Robert W. Colman

Temple University

Publications: 36

Manfred Schmitt

Manfred Schmitt

Technical University of Munich

Publications: 34

Steven L. Gonias

Steven L. Gonias

University of California, San Diego

Publications: 26

Viktor Magdolen

Viktor Magdolen

Technical University of Munich

Publications: 26

Douglas D. Boyd

Douglas D. Boyd

The University of Texas MD Anderson Cancer Center

Publications: 23

Alvin H. Schmaier

Alvin H. Schmaier

University Hospitals of Cleveland

Publications: 20

Berhane Ghebrehiwet

Berhane Ghebrehiwet

Stony Brook University

Publications: 19

Peter A. Andreasen

Peter A. Andreasen

Aarhus University

Publications: 19

Keld Danø

Keld Danø

Copenhagen University Hospital

Publications: 16

Horst Kessler

Horst Kessler

Technical University of Munich

Publications: 16

Klaus T. Preissner

Klaus T. Preissner

University of Giessen

Publications: 15

Francesco Blasi

Francesco Blasi

University of Milan

Publications: 14

Peter Carmeliet

Peter Carmeliet

KU Leuven

Publications: 14

Mark D. Hulett

Mark D. Hulett

La Trobe University

Publications: 13

Trending Scientists

Norman C. Beaulieu

Norman C. Beaulieu

Beijing University of Posts and Telecommunications

Eric Atwell

Eric Atwell

University of Leeds

Liming Chen

Liming Chen

École Centrale de Lyon

Rolando Guidelli

Rolando Guidelli

University of Florence

Wenqing Qin

Wenqing Qin

Central South University

Susan Strome

Susan Strome

University of California, Santa Cruz

Martin T. Dokulil

Martin T. Dokulil

University of Innsbruck

mutsuo sekiguchi

mutsuo sekiguchi

Fukuoka Dental College

Clare M. Goodess

Clare M. Goodess

University of East Anglia

John J. Sansalone

John J. Sansalone

University of Florida

Adrian J. Dunn

Adrian J. Dunn

Louisiana State University

Ena Wang

Ena Wang

Nurix Therapeutics

Philip J. Stephens

Philip J. Stephens

Foundation Medicine

Márta Korbonits

Márta Korbonits

Queen Mary University of London

Paolo Verdecchia

Paolo Verdecchia

University of Perugia

Something went wrong. Please try again later.